



Correction

Correction: Clinical Validation of an Ultra High-Throughput Spiral Microfluidics for the Detection and Enrichment of Viable Circulating Tumor Cells

The PLOS ONE Staff

There is an error in the 10th sentence of the first paragraph in the Enrichment of putative CTCs from patients with metastatic breast and lung cancer section of the Results. The correct sentence is: This population varied in distribution across all samples, and was present at an average proportion of $48.8 \pm 15.5\%$ of the total nucleated cells (Table S2 in File S1).

Table S2 in File S1 is incorrect. The headings for the last three columns are incorrectly labeled and the total nucleated cell counts are incorrect. Please view the correct Table S2 below.

Supporting Information

Table S2. List of patient samples for clinical validation. Clinico-pathological characteristics are provided for patients with metastatic lung or breast cancer who provided samples for CTC enumeration. Samples may be serially obtained from a single patient and these are indicated by the patient number. C: Cycle, D: Day. Post suture pre AC samples are stated to be <3 weeks post-treatment.

(DOCX)

Reference

1. Khoo BL, Warkiani ME, Tan DS-W, Bhagat AAS, Irwin D, et al. (2014) Clinical Validation of an Ultra High-Throughput Spiral Microfluidics for the Detection and Enrichment of Viable Circulating Tumor Cells. PLoS ONE 9(7): e99409. doi:10.1371/journal.pone.0099409

Citation: The PLOS ONE Staff (2014) Correction: Clinical Validation of an Ultra High-Throughput Spiral Microfluidics for the Detection and Enrichment of Viable Circulating Tumor Cells. PLoS ONE 9(10): e111296. doi:10.1371/journal.pone.0111296

Published: October 10, 2014

Copyright: © 2014 The PLOS ONE Staff. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.